Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study

被引：0

作者：

Yves Horsmans

Jocelyn Zhou

Mateva Liudmila

George Golor

Oren Shibolet

Michelle Quinlan

Corinne Emotte

Hildegard Boss

Henry Castro

Dalila Sellami

Richard A. Preston

机构：

[1] Cliniques Saint-Luc,Early Phase Clinical Unit

[2] UCL St Luc Bruxelles,Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine

[3] Novartis Pharmaceuticals Corporation,Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine

[4] UMHAT “Sveti Ivan Rilski” EAD,undefined

[5] PAREXEL International GmbH,undefined

[6] Tel Aviv Sourasky Medical Center (Ichilov),undefined

[7] Novartis Pharma AG,undefined

[8] University of Miami,undefined

[9] Florida International University,undefined

[10] Bristol Myers Squibb (BMS),undefined

来源：

Clinical Pharmacokinetics | 2018年 / 57卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：345 / 354

页数：9

共 50 条

[21] EFFECT OF HEPATIC IMPAIRMENT ON COBIMETINIB PHARMACOKINETICS: AN OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY.
Templeton, I.
Kshirsagar, S.
Deng, Y.
Choong, N.
Chang, I.
Georgescu, I.
Musib, L.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S102 - S102
[22] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
Gardin, Anne
Dodman, Angela
Kalluri, Sampath
Neelakantham, Srikanth
Tan, Xuemei
Legangneux, Eric
Shakeri-Nejad, Kasra
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
[23] Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
Marbury, Thomas
El-Hashimy, Mona
Blumenstein, Lars
Letellier, Franck
Sengupta, Tirtha
Lorenzo, Sebastien
Preston, Richard Alfred
JOURNAL OF CANCER, 2023, 14 (09): : 1571 - 1578
[24] Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study
Stangier, Joachim
Rathgen, Karin
Stahle, Hildegard
Mazur, Dago
CLINICAL PHARMACOKINETICS, 2010, 49 (04) : 259 - 268
[25] Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran EtexilateAn Open-Label, Parallel-Group, Single-Centre Study
Joachim Stangier
Karin Rathgen
Hildegard Stähle
Dago Mazur
Clinical Pharmacokinetics, 2010, 49 : 259 - 268
[26] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
Shakeri-Nejad, Kasra
Aslanis, Vassilios
Veldandi, Uday Kiran
Gardin, Anne
Zaehringer, Andreas
Dodman, Angela
Su, Zhenzhong
Legangneux, Eric
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 41 - 53
[27] A Phase-I, Open-Label, Single-Dose Study of the Pharmacokinetics of Buparlisib in Subjects With Mild to Severe Hepatic Impairment
Csonka, Denes
Hazel, Katharine
Waldron, Edward
Lorenzo, Sebastien
Duval, Vincent
Trandafir, Lucia
Kobalava, Zhanna D.
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (03): : 316 - 323
[28] An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics
Mendell, J.
Johnson, L.
Ridout, G.
He, L.
Chen, S.
EUROPEAN HEART JOURNAL, 2012, 33 : 343 - 343
[29] An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
Li, Yan
Wang, Xiaomin
Liu, Liangang
Zhang, Chengyue
Gomez, Diana
Reyes, Josephine
Palmisano, Maria
Zhou, Simon
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (03): : 346 - 354
[30] Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment
Kuipers, Mirjam
Smulders, Ronald
Krauwinkel, Walter
Hoon, Timothy
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (04) : 405 - 412

← 1 2 3 4 5 →